股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國天元醫療集團有限公司 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00557 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,720,615,042 | HKD | | 1 | HKD | | 2,720,615,042 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 2,720,615,042 | HKD | | 1 | HKD | | 2,720,615,042 | 本月底法定/註冊 ...

CHINA TIAN YUAN HEALTHCARE GROUP LIMITED 中國天元醫療集團有限公司 （於開曼群島註冊成立之有限公司） （股份代號：557） 進一步公佈－ 香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 遵守上市規則 誠如該等公佈所披露，收購事項的代價乃由賣方與本集團按一般商業條款經公 平磋商後釐定，其中包括根據獨立估值師編製之估值報告所載的收益法中的現 金流量貼現法釐定目標公司於二零二五年十月三十一日（「評估基準日」）之股東 全部權益價值，為人民幣3,068,000元。 鑒於獨立估值師於編製估值報告時採納收益法中的現金流量貼現法，故有關估 值構成上市規則第14.61條項下之盈利預測。本公佈乃遵照上市規則第14.60A而 作出。 1 根據上市規則第14.60A(2)條，本公司已委聘其核數師國富浩華（香港）會計師事 務所有限公司就獨立估值師編製的估值報告所採用的折現現金流量計算之算術 準確性作出報告。國富浩華（香港）會計師事務所有 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 CHINA TIAN YUAN HEALTHCARE GROUP LIMITED 中國天元醫療集團有限公司 （於開曼群島註冊成立之有限公司） （股份代號：557） 申請豁免遵守上市規則第14.60A條 茲提述本公司日期為二零二五年十二月三十一日有關買方擬以人民幣2,100,000 元作為代價向賣方收購目標公司的70%股權的公佈、日期為二零二六年一月八 日有關補充協議的公佈（「該等公佈」）。除文義另有所指外，本公佈所用詞彙應與 該等公佈所界定者具有相同涵義。 誠如該等公佈所述，本公司須根據第14.60A條於二零二六年一月二十二日或之 前另作公佈。 由於本公司核數師需要額外時間編製及落實關於目標公司盈利預測的本公司核 數師函件，本公司已申請豁免嚴格遵守上市規則第14.60A條，將根據上市規則第 14.60A條刊發公佈及向聯交所提交所需資料的最後期限延長至二零二六年一月 三十日（「豁免」）。 本公司將適時根據 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 1 CHINA TIAN YUAN HEALTHCARE GROUP LIMITED 中國天元醫療集團有限公司 （於開曼群島註冊成立之有限公司） （股份代號：557） 有關收購目標公司70%股權之 須予披露交易之補充協議 茲提述本公司日期為二零二五年十二月三十一日有關買方擬以人民幣2,100,000 元作為代價向賣方收購目標公司的70%股權的公佈（「該公佈」）。除文義另有所指 外，本公佈所用詞彙應與該公佈所界定者具有相同涵義。 誠如該公佈所述，根據股權轉讓協議，在交接時賣方應自行將目標公司的註冊 資本減少至實繳相符，使目標公司的註冊資本全部完成實繳，買方應提供必要 的配合（「減資程序」）。 補充協議 於二零二六年一月八日，在審慎評估並綜合考慮相關法律要求與業務實際情況 後，買方與賣方一及賣方二就股權轉讓協議訂立了一份補充協議（「補充協議」）， 據此： 1. 買方及賣方同意，減資程序不再進行。因此，買方及 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國天元醫療集團有限公司 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00557 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,720,615,042 | HKD | | | 1 HKD | | 2,720,615,042 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 2,720,615,042 | HKD | | | 1 HKD | | 2,720,615,042 | FF301 I ...

Group 1 - The company Tianyuan Medical (00557.HK) announced a share transfer agreement to acquire 70% of the target company Ningxia Deshang Clinic for a total consideration of RMB 2.1 million [1] - The acquisition involves the buyer obtaining 60% and 10% of the target company's shares from two sellers, with the transaction subject to certain conditions being met [1] - Following the completion of the transaction, the ownership structure will be 70% for the buyer, 20% for seller one, and 10% for seller two, with the target company becoming an indirect non-wholly owned subsidiary of the company [1] Group 2 - The acquisition is expected to enhance the company's control over the target, which is projected to continue generating revenue primarily from providing health check services in China [2] - The target company's health check center has an operational area of approximately 3,869 square meters and employs 44 staff, including 6 senior physicians, indicating its competitive strength in the region [2] - This acquisition aligns with the company's strategy to expand its medical services in China, allowing for resource integration and synergy, thereby supporting ongoing growth in the Chinese healthcare market [2]

Core Viewpoint - Tianyuan Medical (00557) plans to acquire a 70% stake in Ningxia Deshang Outpatient Department Co., Ltd. for RMB 2.1 million, enhancing its presence in the Chinese medical service sector [1] Group 1: Acquisition Details - The acquisition involves Tianyuan Medical's indirect wholly-owned subsidiary, Zhongning Lekang Medical Technology Co., Ltd. [1] - The target company is established to conduct physical examination services in China [1] - The acquisition price is set at RMB 2.1 million [1] Group 2: Operational Insights - The target company's physical examination center has an operational area of approximately 3,869 square meters and employs 44 staff members, including 6 senior physicians [1] - The center is expected to continue generating revenue primarily from providing physical examination services in China [1] Group 3: Strategic Alignment - The acquisition aligns with the company's strategy to expand its medical services in China and strengthen its existing business in the medical sector [1] - The company aims to leverage the target's regional advantages and business foundation for resource integration and synergy [1] - The board believes that the acquisition will create synergistic effects and provide solid momentum for future growth [1]

Core Viewpoint - Tianyuan Medical (00557) is acquiring a 70% stake in Ningxia Deshang Outpatient Department Co., Ltd. for RMB 2.1 million, aiming to enhance its presence in the medical services sector in China [1] Group 1: Acquisition Details - The acquisition involves Tianyuan Medical's indirect wholly-owned subsidiary, Zhongning Lekang Medical Technology Co., Ltd. [1] - The target company is established to conduct physical examination services in China [1] - The expected area of operation for the target company's examination center is approximately 3,869 square meters, employing 44 staff members, including 6 senior physicians [1] Group 2: Strategic Implications - The acquisition aligns with the company's strategy to expand its medical services in China [1] - It is seen as an opportunity to strengthen existing operations in the medical business segment [1] - The company anticipates that the acquisition will create synergies and support ongoing growth in the Chinese medical market [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 CHINA TIAN YUAN HEALTHCARE GROUP LIMITED 中國天元醫療集團有限公司 （於開曼群島註冊成立之有限公司） （股份代號：557） 須予披露交易－ 收購目標公司70%股權 交割須待股權轉讓協議中訂明的若干先決條件達成後，方可作實。概不保證任 何該等條件將會達成。因此，收購事項未必會進行。股東及潛在投資者於買賣 本公司證券時務請審慎行事。 緒言 董事會欣然宣佈，於二零二五年十二月三十一日（聯交所交易時段後），買方（本 公司之間接全資附屬公司）與賣方一及賣方二訂立股權轉讓協議，據此，買方有 條件同意收購而賣方有條件同意出售目標股權，代價為人民幣2,100,000元（相等 於約2,331,000港元）。交接及交割須待（其中包括）股權轉讓協議所載先決條件滿 足或獲豁免（倘適用）後，方可作實。 股權轉讓協議 股權轉讓協議之主要條款概述如下： 董事會欣然宣佈，於二零二五年十二月三十一 ...

Core Viewpoint - Tianyuan Medical (00557) announced that Tianyuan Manganese informed the company about an internal equity restructuring, where Ningxia Tianyuan Group will transfer 100% of its shares in Tianyuan Manganese to Ningxia Tianyuan Co., Ltd. This restructuring was completed on December 17, 2025 [1] Group 1 - Prior to the restructuring, Tianyuan Manganese directly held approximately 66.69% of the total issued shares of the company [1] - After the restructuring, Tianyuan Manganese is directly held 100% by Ningxia Tianyuan Co., Ltd., while Ningxia Tianyuan Co., Ltd. is directly held 100% by Ningxia Tianyuan Group [1] - The ultimate controlling shareholder remains Mr. Jia, who holds approximately 99.99% of Ningxia Tianyuan Group [1] Group 2 - The board of directors believes that the restructuring will not have any significant impact on the management and operations of the company [1]